(Q33376503)

26 July 2017

title

Retreatment with yttrium-90 ibritumomab tiuxetan in patients with B-cell non-Hodgkin's lymphoma (English)

1 reference

26 July 2017

Sui Shen

6

0 references

author name string

Jatin Shah

1

1 reference

26 July 2017

Wenquan Wang

2

1 reference

26 July 2017

V Douglas Harrough

3

1 reference

26 July 2017

Wayne Saville

4

1 reference

26 July 2017

Ruby Meredith

5

1 reference

26 July 2017

John Mueh

7

1 reference

26 July 2017

John Lister

8

1 reference

26 July 2017

Sri Jasthy

9

1 reference

26 July 2017

Gregory Maggass

10

1 reference

26 July 2017

Charles McKay

11

1 reference

26 July 2017

Richard Krumdieck

12

1 reference

26 July 2017

Morgan Tharp

13

1 reference

26 July 2017

Christine Winter

14

1 reference

26 July 2017

Stephanie Gregory

15

1 reference

26 July 2017

William Buchholz

16

1 reference

26 July 2017

Sanjay Awasthi

17

1 reference

26 July 2017

Samuel Jacobs

18

1 reference

26 July 2017

Harold Chung

19

1 reference

26 July 2017

James Egner

20

1 reference

26 July 2017

Albert F Lobuglio

21

1 reference

26 July 2017

Andres Forero

22

1 reference

26 July 2017

publication date

1 September 2007

1 reference

26 July 2017

1 reference

26 July 2017

volume

48

1 reference

26 July 2017

issue

9

1 reference

26 July 2017

page(s)

1736-1744

1 reference

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F10428190701528517

The radioisotope contributes significantly to the activity of radioimmunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701528517

Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for patients with relapsed CD20+ B-cell non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701528517

Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701528517

Yttrium 90 ibritumomab tiuxetan in lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701528517

Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701528517

Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701528517

Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701528517

Antilymphoma treatments given subsequent to Yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701528517

Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701528517

Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701528517

Full-dose 90Y ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701528517

Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701528517

10.1080/10428190701528517

21 January 2018

Identifiers

DOI

1 reference

26 July 2017

1 reference